Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

10.44

Mkt cap

365M

Volume

71K

High

10.63

P/E Ratio

-5.38

52-wk high

16.08

Low

10.35

Div yield

N/A

52-wk low

6.76

Nyxoah SA (NASDAQ: NYXH) has reduced the maximum amount of ordinary shares available for issuance under its 'at-the-market' offering by 1,569,139 shares, resulting in a new maximum of 4,430,861 shares. This change increases the authorized capital available to the board by EUR 269,579.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 8:37 pm

Nyxoah SA (NASDAQ:NYXH) has announced a proposed underwritten public offering of its ordinary shares in the United States. The offering may also include shares sold in a private offering to qualified or institutional investors outside the U.S. The company will grant underwriters a 30-day option to purchase additional shares up to 15% of the number of shares sold. The offering's size and terms are not yet disclosed and are subject to market conditions.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 8:21 pm

Nyxoah shares are trading higher after the company reported better-than-expected Q1 sales results.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 4:14 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Nyxoah (NASDAQ:NYXH) and maintained a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 3:57 pm

Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $20 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 3:33 pm

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:35 pm

Stifel analyst Jonathan Block maintains a Buy rating on Nyxoah (NASDAQ:NYXH) with a $27 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:51 am

Nyxoah (NASDAQ:NYXH) reported Q1 2024 earnings with a GAAP EPS of $(0.45), missing the $(0.42) estimate, but sales of $1.33M exceeded the $1.31M estimate. This represents a significant improvement in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:18 pm

Fastenal Company's shares dropped by around 7% due to disappointing Q1 FY24 financial results, with sales and EPS missing consensus estimates. Other stocks experienced significant movements, with Rallybio Corporation, Rent the Runway, and Eliem Therapeutics among the top gainers, while Aptevo Therapeutics, Enlivex Therapeutics, and AVITA Medical led the losers.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 5:33 pm

CarMax, Inc. reported lower-than-expected Q4 earnings, leading to a 9.1% drop in pre-market trading. Other stocks like The Lovesac Company, Nyxoah S.A., AVITA Medical, Inc., DigiAsia Corp., Nanobiotix S.A., Grifols, S.A., Fastenal Company, and Mercury General Corporation also saw declines in pre-market trading due to various reasons including disappointing earnings, downgrades, and upcoming earnings expectations.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 12:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.